Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| aptamers, classical and mirror ones | 4905 | 222716-86-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
a pegylated modified oligonucleotide that binds with high specificity and affinity to extracellular Vascular Endothelial Growth Factor (VEGF165) inhibiting its activity, VEGF is a secreted protein that induces angiogenesis, vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of AMD
|
None
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 17, 2004 | FDA | VALEANT PHARMS LLC |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | S01LA03 | SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents |
| FDA CS | M0015278 | Oligonucleotides |
| FDA CS | M0483498 | Aptamers, Nucleotide |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Exudative age-related macular degeneration | indication | 414173003 | DOID:10873 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Vascular endothelial growth factor A | Secreted | ANTAGONIST | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D05386 | KEGG_DRUG |
| 4024940 | VUID |
| N0000171612 | NUI |
| 4024940 | VANDF |
| CHEMBL1201421 | ChEMBL_ID |
| CHEMBL2108752 | ChEMBL_ID |
| C495058 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6836 | IUPHAR_LIGAND_ID |
| DB04895 | DRUGBANK_ID |
| 498509 | RXNORM |
| 19106 | MMSL |
| 64008 | MMSL |
| 008794 | NDDF |
| 008795 | NDDF |
| 416058004 | SNOMEDCT_US |
| 416268001 | SNOMEDCT_US |
| 423490007 | SNOMEDCT_US |
| C1531015 | UMLSCUI |
| CHEBI:749454 | CHEBI |
| 8215 | INN_ID |
| 2H1PA8H1EN | UNII |
| C430291 | MESH_SUPPLEMENTAL_RECORD_UI |
None